Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.54 |
| ▸ | CMA1 | P23946 | 2/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | DPP3 | Q9NY33 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alacepril SCHEMBL11460465 | 1.00 | ACE (0.55) | ACESLC6A2ACE2CMA1OPRM1 | |
| Alacepril SCHEMBL5058556 | 1.00 | ACE (0.55) | ACESLC6A2ACE2CMA1OPRM1 | |
| Alacepril SCHEMBL20126832 | 1.00 | ACE (0.55) | ACESLC6A2ACE2CMA1OPRM1 | |
| Alacepril SCHEMBL683027 | 1.00 | ACE (0.55) | ACESLC6A2ACE2CMA1OPRM1 | |
| Alacepril SCHEMBL34559 | 1.00 | ACE (0.55) | ACESLC6A2ACE2CMA1OPRM1 | |
| Alacepril SCHEMBL3204613 | 1.00 | ACE (0.55) | ACESLC6A2ACE2CMA1OPRM1 | |
| Alacepril SCHEMBL28035498 | 1.00 | ACE (0.55) | ACESLC6A2ACE2CMA1OPRM1 | |
| Alacepril SCHEMBL11458085 | 0.95 | ACE (0.51) | ACESLC6A2ACE2CMA1OPRM1 | |
| SCHEMBL11282561 | 0.93 | SLC6A2 (0.56) | ACESLC6A2CMA1OPRM1 | |
| SCHEMBL683119 | 0.93 | SLC6A2 (0.56) | ACESLC6A2CMA1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0007477-B1 | 1-(3-MERCAPTO-2-METHYLPROPANOYL)PROLYL AMINO ACID DERIVATIVES AND SALTS THEREOF, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | Dainippon Pharmaceutical Co., Ltd. (JP) | 1982-04-28 | — | — | EP | claimed |
| US-4248883-A | ANTIHYPERTENSION AGENTS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1981-02-03 | — | — | US | claimed |
| EP-0007477-A1 | 1-(3-Mercapto-2-methylpropanoyl)prolyl amino acid derivatives and salts thereof, processes for their preparation, and pharmaceutical compositions containing such compounds | Dainippon Pharmaceutical Co., Ltd. (JP) | 1980-02-06 | — | — | EP | claimed |
| JP-11222439-A | — | — | None | — | — | JP | disclosed |
| JP-56092848-A | — | — | None | — | — | JP | disclosed |
| JP-56145220-A | — | — | None | — | — | JP | disclosed |
| EP-2198869-B1 | TREHALOSE FOR THE TREATMENT OR PREVENTION OF VASOSPASM | NEXT 21 K K (JP) | 2015-09-16 | — | — | EP | disclosed |
| US-8283337-B2 | Therapeutic or prophylactic agent for vasoconstriction | NEXT21 K.K. (JP) | 2012-10-09 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| EP-2382975-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2377531-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-5846517-A | Methods for diagnostic imaging using a renal contrast agent and a vasodilator | IMARX PHARMACEUTICAL CORP. (US) | 1998-12-08 | — | — | US | disclosed |
| EP-0105696-B1 | OPTICALLY ACTIVE N-SUBSTITUTED PHENYLALANINOLS AND USE THEREFOR | Dainippon Pharmaceutical Co., Ltd. (JP) | 1986-01-02 | — | — | EP | disclosed |
| US-4536601-A | USE FOR RESOLUTION OF D-3-ACETHYLTHIO-2-METHYLPROPIONIC ACID | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1985-08-20 | — | — | US | disclosed |
| EP-0105696-A1 | Optically active N-substituted phenylalaninols and use therefor | Dainippon Pharmaceutical Co., Ltd. (JP) | 1984-04-18 | — | — | EP | disclosed |
| EP-0007477-B1 | 1-(3-MERCAPTO-2-METHYLPROPANOYL)PROLYL AMINO ACID DERIVATIVES AND SALTS THEREOF, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | Dainippon Pharmaceutical Co., Ltd. (JP) | 1982-04-28 | — | — | EP | disclosed |
| JP-S56145220-A | ANTIHYPERTENSIVE AGENT CONTAINING PROLYLAMINO ACID DERIVATIVE AND DIURETIC AGENT AS MAIN CONSTITUENT | DAINIPPON PHARMACEUT CO LTD | 1981-11-11 | — | — | JP | disclosed |
| JP-S5692848-A | PREPARATION OF 1- 3-LOWER ALAKNOYLTHIO-2-METHYLPROPANOYL PROLYLPHENYLALANINE | DAINIPPON PHARMACEUT CO LTD | 1981-07-27 | — | — | JP | disclosed |
| US-4248883-A | ANTIHYPERTENSION AGENTS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1981-02-03 | — | — | US | disclosed |
| EP-0007477-A1 | 1-(3-Mercapto-2-methylpropanoyl)prolyl amino acid derivatives and salts thereof, processes for their preparation, and pharmaceutical compositions containing such compounds | Dainippon Pharmaceutical Co., Ltd. (JP) | 1980-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | ACE 6/4885SLC6A2 376/4885ACE2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.